Therefore, substantial revenue opportunity for conventional disease-modifying antirheumatic drugs (DMARDs) remains in early lines of therapy.
因此，在早期治疗中，常规抗风湿性关节炎疾病缓解用药还有很大市场。
Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis.
【译】合成和生物制剂的安全性：系统的文献回顾，通知2013更新的EULAR建议类风湿性关节炎的管理。
In recent years, biologic disease-modifying anti-rheumatic drugs (DMARDs) have been introduced that can help to modify this irregular immune response and improve symptoms of the disease.
近年来已生产出缓解疾病的抗风湿性生物制剂(DMARDs)，这能有助于改善不规则的免疫应答、改善这种疾病的症状。
In recent years, biologic disease-modifying anti-rheumatic drugs (DMARDs) have been introduced that can help to modify this irregular immune response and improve symptoms of the disease.
近年来已生产出缓解疾病的抗风湿性生物制剂(DMARDs)，这能有助于改善不规则的免疫应答、改善这种疾病的症状。
应用推荐